Prevalence of Human T-Cell Lymphotropic Virus Type 2 Infection in General Population of Mashhad, Iran

Document Type : Original Article (s)

Authors

1 Associate Professor, Inflammation and Inflammatory Diseases Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

2 Associate Professor, Research Center for HIV/AIDS, HTLV and Viral Hepatitis, Iranian Academic Center for Education, Culture and Research (ACECR), Mashhad Branch, Mashhad, Iran

3 Research Center for HIV/AIDS, HTLV and Viral Hepatitis, Iranian Academic Center for Education, Culture and Research (ACECR), Mashhad Branch, Mashhad, Iran

4 Instructor, Research Center for HIV/AIDS, HTLV and Viral Hepatitis, Iranian Academic Center for Education, Culture and Research (ACECR), Mashhad Branch, Mashhad, Iran

5 Instructor, Center of Genetic, Pathological and Medical Diagnostic Services, Iranian Academic Center for Education, Culture and Research (ACECR), Mashhad Branch, Mashhad, Iran

6 Center of Genetic, Pathological and Medical Diagnostic Services, Iranian Academic Center for Education, Culture and Research (ACECR), Mashhad Branch, Mashhad, Iran

7 Associate Professor, Department of Neurology, Ghaem Hospital, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

8 Assistant Professor, Inflammation and Inflammatory Diseases Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

9 Professor, Allergy Research Centre, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

10 Instructor, Inflammation and Inflammatory Diseases Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

11 Department of Internal Medicine, American University of Beirut, Beirut, Lebanon

Abstract

Background: Northeastern Iran, particularly Mashhad city, is an endemic area for human T-cell lymphotropic virus type 1 (HTLV-I) infection; although, there is no data on the prevalence of HTLV-II in this region. This cross-sectional study aimed to evaluate the prevalence of HTLV-II infection in general population of Mashhad.Methods: From general population of Mashhad, 1678 individuals were selected using multistage cluster sampling method. Serum samples were tested for the presence of HTLV antibodies using enzyme-linked immunosorbent assay (ELISA) assay. To confirm HTLV-II infection, TAX gene and long terminal repeat (LTR) region were amplified using designed specific primers by nested polymerase chain reaction (nested PCR) technique.Findings: From 1678 individuals, 1654 serum samples were taken, of which, 56 were positive for HTLV antibodies via ELISA method. All reactive samples were examined by nested PCR for the presence of HTLV-II provirus. None of the cases were positive for HTLV-II infection.Conclusion: The results of present study demonstrate no evidence of HTLV-II infection in the general population of Mashhad. However, it is recommended to investigate the prevalence of the virus among high-risk groups, specially injecting drug users in this region.

Keywords

References

  1. Lowis GW, Sheremata WA, Minagar A. Epidemiologic features of HTLV-II: serologic and molecular evidence. Ann Epidemiol 2002; 12(1): 46-66.
  2. Verdonck K, Gonzalez E, Van DS, Vandamme AM, Vanham G, Gotuzzo E. Human T-lymphotropic virus 1: recent knowledge about an ancient infection. Lancet Infect Dis 2007; 7(4): 266-81.
  3. Proietti FA, Carneiro-Proietti AB, Catalan-Soares BC, Murphy EL. Global epidemiology of HTLV-I infection and associated diseases. Oncogene 2005; 24(39): 6058-68.
  4. Vrielink H, Reesink HW. HTLV-I/II prevalence in different geographic locations. Transfus Med Rev 2004; 18(1): 46-57.
  5. Manns A, Hisada M, La GL. Human T-lymphotropic virus type I infection. Lancet 1999; 353(9168): 1951-8.
  6. Matsuoka M, Jeang KT. Human T-cell leukemia virus type I at age 25: a progress report. Cancer Res 2005; 65(11): 4467-70.
  7. Gastaldello R, Hall WW, Gallego S. Seroepidemiology of HTLV-I/II in Argentina: an overview. J Acquir Immune Defic Syndr 2004; 35(3): 301-8.
  8. Yoshizaki H, Kitamura K, Oki A, Yahara S, Yamanaka R, Fukushima Y, et al. Human T-lymphotropic virus type II in Japan. Jpn J Cancer Res 1996; 87(1): 1-4.
  9. Murphy EL, Watanabe K, Nass CC, Ownby H, Williams A, Nemo G. Evidence among blood donors for a 30-year-old epidemic of human T lymphotropic virus type II infection in the United States. J Infect Dis 1999; 180(6): 1777-83.
  10. Lee HH, Galli C, Burczak JD, Biffoni F, De SG, De VS, et al. A multicentric seroepidemiological survey of HTLV-I/II in Italy. Clin Diagn Virol 1994; 2(3): 139-47
  11. Toro C, Rodes B, Bassani S, Jimenez V, Tuset C, Brugal MT, et al. Molecular epidemiology of HTLV-2 infection among intravenous drug users in Spain. J Clin Virol. 2005; 33(1): 65-70.
  12. .Rezvan H, Ahmadi J, Farhadi M. A cluster of HTLV1 infection in northeastern of Iran. Transfusion Today 1996; 7: 8-9.
  13. Tarhini M, Kchour G, Zanjani DS, Rafatpanah H, Otrock ZK, Bazarbachi A, et al. Declining tendency of human T-cell leukaemia virus type I carrier rates among blood donors in Mashhad, Iran. Pathology 2009; 41(5): 498-9.
  14. Rafatpanah H, Hedayati-Moghaddam MR, Fathimoghadam F, Bidkhori HR, Shamsian SK, Ahmadi S, et al. High prevalence of HTLV-I infection in Mashhad, Northeast Iran: a population-based seroepidemiology survey. J Clin Virol 2011; 52(3): 172-6.
  15. Pourkarim MR, Khamisipour GR, Hajiani GR, Tahmasebi R, Ardeshirdavani N. Seroepidemiological investigation of HTLV I,II infection among Busherian multi- transfused patients in 2003. Sci J Iran Blood Transfus Organ 2005; 2(4): 99-104. [In Persian].
  16. Rafatpanah H, Fathimoghadam F, Shahabi M, Eftekharzadeh I, Hedayati-Moghaddam M, Valizadeh N, et al. No Evidence of HTLV-II Infection Among Immonoblot Indeterminate Samples Using Nested PCR in Mashhad, Northeast of Iran. Iran J Basic Med Sci 2013; 16(3): 229-34.
  17. Khameneh ZR, Baradaran M, Sepehrvand N. Survey of the seroprovalence of HTLV I/II in hemodialysis patients and blood donors in Urmia. Saudi J Kidney Dis Transpl 2008; 19(5): 838-41.
  18. Karimi A, Nafici M, Imani R. Comparison of human T-cell leukemia virus type-1 (HTLV-1) seroprevalence in high risk patients (thalassemia and hemodialysis) and healthy individuals from Charmahal-Bakhtiari province, Iran. Kuwait Med J 2007; 39(3): 259-61.
  19. de Lima WM, Esteves FA, Torres MC, Pires ES. Prevalence of human T-cell lymphotropic virus types 1 and 2 in blood donors of the Caruaru Blood Center (Hemope). Rev Bras Hematol Hemoter 2013; 35(4): 268-71.
  20. Giuliani M, Rezza G, Lepri AC, Di CA, Maini A, Crescimbeni E, et al. Risk factors for HTLV-I and II in individuals attending a clinic for sexually transmitted diseases. Sex Transm Dis 2000; 27(2): 87-92.
  21. Chang YB, Kaidarova Z, Hindes D, Bravo M, Kiely N, Kamel H, et al. Seroprevalence and demographic determinants of human T-lymphotropic virus type 1 and 2 infections among first-time blood donors--United States, 2000-2009. J Infect Dis 2014; 209(4): 523-31.
  22. Ma Y, Zheng S, Wang N, Duan Y, Sun X, Jin J, et al. Epidemiological analysis of HTLV-1 and HTLV-2 infection among different population in Central China. PLoS One 2013; 8(6): e66795.
  23. Ardalan N, Abdi M, Rahimian Zarif B, Amini A, Memari F, Heydari E, et al. Prevalence of human T-lymphotropic virus types I&II among high risk groups in Sanandaj in 2010. Sci J Kurdistan Univ Med Sci 2013; 18(2): 51-7. [In Persian].
  24. Rouhani Rahbar A, Rooholamini S, Khoshnood K. Prevalence of HIV infection and other blood-borne infections in incarcerated and non-incarcerated injection drug users (IDUs) in Mashhad, Iran. Int J Drug Policy 2004; 15(2): 151-5.
Journal of Isfahan Medical School
Volume 32, Issue 316 - Serial Number 316
November and December 2015
Pages 2261-2268

Files

History

  • Receive Date: 14 October 2014
  • Revise Date: 02 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics